Kymera Therapeutics (NASDAQ: KYMR) details KT-621 BroADen trial data

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. reported that it hosted a conference call on December 8, 2025 to discuss results from its BroADen Phase 1b atopic dermatitis patient trial of KT-621, described as a first-in-class, oral STAT6 degrader. The company furnished a related slide presentation as Exhibit 99.1, noting that this material is provided for informational purposes and is not deemed “filed” for liability under Section 18 of the Exchange Act or automatically incorporated into other securities filings. Kymera also stated it undertakes no obligation to update, supplement, or amend the slide materials.

false 0001815442 0001815442 2025-12-08 2025-12-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 8, 2025

KYMERA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39460		81-2992166
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

Kymera Therapeutics, Inc.

500 North Beacon Street, 4th Floor

Watertown, Massachusetts 02472

(Address of principal executive offices, including zip code)

(857) 285-5300

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trade Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		KYMR		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On December 8, 2025, Kymera Therapeutics, Inc. (the “Company”) hosted a conference call to discuss the results from the Company’s BroADen Phase 1b atopic dermatitis patient trial of KT-621, a first-in-class, oral STAT6 degrader. A form of the slide presentation is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01. Exhibits

(d) Exhibits

Exhibit No.		Description
99.1		Kymera Therapeutics, Inc. slide presentation, dated December 8, 2025, furnished herewith.
104		Cover Page Interactive Data

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Kymera Therapeutics, Inc.
Date: December 8, 2025				By:		/s/ Nello Mainolfi
						Nello Mainolfi, Ph.D

FAQ

What did Kymera Therapeutics (KYMR) disclose about KT-621 on December 8, 2025?

Kymera Therapeutics disclosed that on December 8, 2025 it hosted a conference call to discuss results from its BroADen Phase 1b atopic dermatitis patient trial of KT-621.

What is KT-621 in Kymera Therapeutics' (KYMR) development pipeline?

KT-621 is described by Kymera Therapeutics as a first-in-class, oral STAT6 degrader, evaluated in patients with atopic dermatitis in the BroADen Phase 1b trial.

What is the BroADen Phase 1b atopic dermatitis trial mentioned by Kymera Therapeutics?

The BroADen Phase 1b trial is an atopic dermatitis patient study conducted by Kymera Therapeutics to evaluate KT-621, its first-in-class, oral STAT6 degrader.

Where can details of Kymera Therapeutics' KT-621 BroADen trial presentation be found?

The slide presentation discussed on the conference call is furnished as Exhibit 99.1 to Kymera Therapeutics' current report, dated December 8, 2025.

Is Kymera Therapeutics' KT-621 slide presentation considered filed with the SEC?

No. The company states that information in Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to its liabilities.

Will Kymera Therapeutics update the KT-621 BroADen trial presentation in the future?

Kymera Therapeutics states that it undertakes no obligation to update, supplement or amend the materials attached as Exhibit 99.1.